Drug Combination Details
| General Information of the Combination (ID: C05252) | |||||
|---|---|---|---|---|---|
| Name | Plumbagin NP Info | + | Celecoxib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | UACC-903 | CVCL_4052 | Cutaneous melanoma | Homo sapiens | ||
| Mel JuSo | CVCL_1403 | Cutaneous melanoma | Homo sapiens | |||
| A375-M | CVCL_B222 | Amelanotic melanoma | Homo sapiens | |||
| 1205Lu | CVCL_5239 | Melanoma | Homo sapiens | |||
| FF2441 | Healthy | Homo sapiens | ||||
| In-vivo Model | Subcutaneous injection of 1.0 * 106 UACC 903 or 1205 Lu melanoma cells were injected above both the left and right rib cages of 4-5 week-old female Athymic-Foxn1nu nude mice. | |||||
| Experimental
Result(s) |
Combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. Cancer Lett. 2017 Jan 28;385:243-250. | |||
